by Southern blotting and hybridization with D 3 -and homozygous than in wild-type mice. Due to its expression in juxtaglomerular cells the D 3 receptor may negab-actin specific probes derived from rat brain RNA. The renal effects of 7-OH-DPAT were not influenced tively affect renin secretion [5] . From these data it was suggested that D 3 receptors-possibly by impairment by the selective D 2 receptor antagonist S(−)-sulpiride but abolished by pre-treatment with the D 3 antag-of the renal excretory capacity for sodium or increased renin excretion-may play a pathogenetic role in some onist 5,6-dimethoxy-2-(di-n-propylamino)indane ( U-99194A). Taken these results together, 7-OH-DPAT forms of hypertension. However, 7-OH-DPAT induced a similar diuresis and natriuresis in spontaneously hyperappears to affect glomerular and tubular function by specific D 3 receptor activation. tensive and Wistar-Kyoto rats [6 ] . In summary, pharmacological activation of dopamine In a second set of experiments renal blood flow (RBF ) was measured by an electromagnetic flow trans-D 3 receptors affects tubular function and renal haemodynamics in anaesthetized rats, the latter possibly by ducer placed on the left renal artery. Also in this setting, 7-OH-DPAT (1.0 mg/kg/min) increased GFR by post-glomerular vasoconstriction. Whether D 3 receptors are involved in the pathophysiology of systemic or renal 19±3%. Interestingly, RBF was significantly reduced by 26±3% compared with baseline. Renal vascular haemodynamics remains to be determined. resistance was significantly elevated by 25±4% due to 7-OH-DPAT infusion. Haemodynamic changes of the Acknowledgements. These studies were supported by grants from the in patients with chronic renal failure during a 6-month by tissue enzymes (e.g. chymases or CAGE ) [3] . While treatment period. We followed a double-blind, randomized, there are an increasing number of reports about the placebo-controlled study [treatment group ( V-group): n=5, potency of Ang II receptor antagonists to lower blood age: 57±7 years, serum creatinine: 365±122mmol/l; placebo pressure in essential hypertension [4] and benefits in group (P-group): n=4, age: 62±11 years, serum creatinine cardiovascular disease [5] , there is not much informa-346±61mmol/l ]. Study parameters included blood pressure, tion about their antihypertensive and antiproteinuric 24 h proteinuria, glomerular filtration rate (GFR) and effect-('nephroprotective') effects in patients with arterial ive renal plasma flow (ERPF ) as determined by inulin and hypertension and impaired renal function.
PAH clearance. Changes in glomerular permselectivity were assessed by measuring the fractional clearances of neutral dextrans by HPLC gel permeation chromatography.
Patients and methods
The effects of the Ang II antagonist valsartan (80 mg/day) on proteinuria and glomerular permselectivity were studied ances) after 6 months of treatment with (A) valsartan 80 mg/day treatment with valsartan 80 mg/day ( V-group, n=5) or placebo (P-group, n=4) in patients with renal failure. The relative changes ( V-group, n=5) or (B) placebo (P-group, n=4) in patients with renal failure. Reference values of healthy controls (n=10) are shown. vs the run-in phase (averaged, set to 100%) are shown and, additionally, the absolute daily excretion (mg/24 h) during run-in and after Data are given as mean±SEM. Differences within the study groups before and after treatment (valsartan/placebo) are tested by Student 6 months of treatment is indicated. Values are given as mean±SEM. Changes vs the run-in phase are indicated by asterisks, *P<0.05.
t-test, *P<0.05, **P<0.01. The differences between baseline values in the study groups and the sieving coefficients of healthy controls Differences between both study groups during the treatment phase are tested by MANOVA and indicated by |~~~~|.
are tested by t-test for independent samples, #P<0.05, ##P<0.01.
The mean pore size radius of the glomerular membrane Results remained unchanged. This effect was independent of glomerular haemodynamic changes ( Figure 2 ). Valsartan lowered the mean arterial pressure on average by 13±7 mmHg during 6 months treatment (P<0.05). Average blood pressure reduction over 6 Conclusions months was significantly different between the V-group and the P-group.
Our findings with the Ang II antagonist valsartan show Baseline serum potassium concentrations in the a sustained reduction in blood pressure and proteinuria V-group moderately increased from 4.4±0.4 mmol/l even in patients with advanced renal failure. While to 4.9±0.5 mmol/l after 3 months of valsartan treat-GFR and ERPF remained nearly stable, this effect ment (P<0.05) and remained almost unchanged could be attributed to an improvement in glomerular thereafter.
permselectivity. A preserved excretory renal function In the V-group, baseline GFR was 20±7ml/min in together with functional benefits in glomerular permsethe run-in period and averaged 18±6ml/min for the lectivity may recommend this class of antihypertensives three measurements during the treatment phase (NS). as a 'nephroprotective alternative' to ACEIs. This will In the P-group, GFR changed from 19±5ml/min to require further long-term studies. 21±8ml/min (NS ). RBF decreased slightly over time from 152±47 to 140±47 ml/min in the V-group and from 143±53 to 129±55 ml/min in the P-group. The References trend between the groups concerning ERPF and RBF was not significantly different with regard to the whole
